Mauriello Alfredo, Correra Adriana, Del Vecchio Gerardo Elia, Grieco Martina, Amata Arianna, Di Micco Pierpaolo, Imbalzano Egidio, Paternoster Mariano, Ascrizzi Antonia, Quagliariello Vincenzo, Maurea Nicola, Giallauria Francesco, D'Andrea Antonello, Russo Vincenzo
S.C. Cardiologia, Istituto Nazionale Tumori, IRCCS, Fondazione "G. Pascale", 80131 Naples, Italy.
Intensive Cardiac Care Unit, San Giuseppe Moscati Hospital, ASL Caserta, 81031 Aversa, Italy.
Biomedicines. 2025 Jun 13;13(6):1462. doi: 10.3390/biomedicines13061462.
Heart failure (HF) is a highly prevalent cardiovascular clinical syndrome. Health care spending on HF treatment is high. Therefore, its treatment has generated a great deal of interest in pharmacological research in recent years. Recent guidelines have introduced several molecules for the treatment of HF that have demonstrated safety, and above all, efficacy. One of the worst aspects of HF is ventricular dyssynchrony (VD) with a wide QRS interval. Currently, the cornerstone of VD therapy is cardiac resynchronization therapy (CRT). Our comprehensive review aims to analyze the effects of new molecules on QRS width and understand whether these molecules can provide benefits.
心力衰竭（HF）是一种高度流行的心血管临床综合征。用于HF治疗的医疗保健支出很高。因此，近年来其治疗在药理学研究中引起了极大的兴趣。最近的指南引入了几种用于治疗HF的分子，这些分子已证明具有安全性，最重要的是具有疗效。HF最糟糕的方面之一是伴有宽QRS间期的心室不同步（VD）。目前，VD治疗的基石是心脏再同步治疗（CRT）。我们的综合综述旨在分析新分子对QRS宽度的影响，并了解这些分子是否能带来益处。
